Regionaal- ja Põllumajandusministeerium ja TS Laevad sõlmisid 10.09.2024 sõitjateveo avaliku teenindamise lepingu seitsmeaastaseks perioodiks algusega 01.10.2026.

Sanofi has received approval for two drugs, Myqorzo (aficamten) for treating obstructive hypertrophic cardiomyopathy (HCM) and Redemplo (plozasiran) for familial chylomicronemia syndrome (FCS). These approvals demonstrate Sanofi's long-term commitment to China and its ambition to provide transformative medicines to patients with unmet medical needs. Myqorzo is a selective cardiac myosin inhibitor designed to improve functional capacity and alleviate symptoms in HCM obstructive patients, while Redemplo is a low-ARN-interfering drug that suppresses apoc-III production, a key target for triglyceride reduction in FCS patients.